ADAPTIVE BIOTECHNOLOGIES CORPORATION Total Liabilities and Equity
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) had Total Liabilities and Equity of $640.68 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-04
- 2026-06-30: Liabilities and Equity $640.68M.
- 2026-03-31: Liabilities and Equity $505.94M.
- 2025-12-31: Liabilities and Equity $512.74M.
- 2025-09-30: Liabilities and Equity $490.61M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $640.68M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $505.94M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $512.74M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $490.61M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $496.64M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $510.85M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $539.38M 10-K · filed 2026-02-26 |
| 2024-09-30 | $558.51M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $584.87M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $620.32M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $661.13M 10-K · filed 2025-03-03 |
| 2023-09-30 | $717.68M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $764.54M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $791.46M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $856.62M 10-K · filed 2024-02-29 |
| 2022-09-30 | $884.21M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $806.63M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $858.19M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $923.34M 10-K · filed 2023-02-14 |
| 2021-09-30 | $992.61M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $1.03B 10-Q · filed 2021-08-04 |
| 2021-03-31 | $1.07B 10-Q · filed 2021-05-05 |
| 2020-12-31 | $1.12B 10-K · filed 2022-02-15 |
| 2020-09-30 | $1.10B 10-Q · filed 2020-11-10 |
| 2020-06-30 | $854.82M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $874.89M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $912.30M 10-K · filed 2021-02-24 |
| 2019-09-30 | $917.39M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $601.39M 10-Q · filed 2019-08-13 |
| 2018-12-31 | $332.69M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |